A high-throughput screen for chemical inhibitors of exocytic transport in yeast.
Most of the components of the membrane and protein traffic machinery were discovered by perturbing their functions, either with bioactive compounds or by mutations. However, the mechanisms responsible for exocytic transport vesicle formation at the Golgi and endosomes are still largely unknown. Both the exocytic traffic routes and the signaling pathways that regulate these routes are highly complex and robust, so that defects can be overcome by alternate pathways or mechanisms. A classical yeast genetic screen designed to account for the robustness of the exocytic pathway identified a novel conserved gene, AVL9, which functions in late exocytic transport. We now describe a chemical-genetic version of the mutant screen, in which we performed a high-throughput phenotypic screen of a large compound library and identified novel small-molecule secretory inhibitors. To maximize the number and diversity of our hits, the screen was performed in a pdr5Delta snq2Delta mutant background, which lacks two transporters responsible for pleiotropic drug resistance. However, we found that deletion of both transporters reduced the fitness of our screen strain, whereas the pdr5Delta mutation had a relatively small effect on growth and was also the more important transporter mutation for conferring sensitivity to our hits. In this and similar chemical-genetic yeast screens, using just a single pump mutation might be sufficient for increasing hit diversity while minimizing the physiological effects of transporter mutations.
Zhang
Lisha
L
Department of Molecular Biosciences, University of Kansas, 1200 Sunnyside Avenue, Lawrence, KS 66045, USA.
Nebane
N Miranda
NM
Wennerberg
Krister
K
Li
Yujie
Y
Neubauer
Valerie
V
Hobrath
Judith V
JV
McKellip
Sara
S
Rasmussen
Lynn
L
Shindo
Nice
N
Sosa
Melinda
M
Maddry
Joseph A
JA
Ananthan
Subramaniam
S
Piazza
Gary A
GA
White
E Lucile
EL
Harsay
Edina
E
D011992:Endosomes / Q000378:metabolism; D005089:Exocytosis / Q000187:drug effects*; D057166:High-Throughput Screening Assays; D012441:Saccharomyces cerevisiae / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology; D029701:Saccharomyces cerevisiae Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction; D054852:Small Molecule Libraries / Q000737:chemistry* / Q000494:pharmacology
D029701:Saccharomyces cerevisiae Proteins; D054852:Small Molecule Libraries
Mol Biol Cell. 2007 Apr;18(4):1203-19
17229886
J Cell Biol. 2002 Jan 21;156(2):271-85
11807092
Annu Rev Genet. 2008;42:27-81
18303986
Methods Enzymol. 2002;350:3-41
12073320
Curr Drug Targets. 2006 Apr;7(4):471-81
16611035
Cell. 1988 Jul 15;54(2):221-7
3390865
Chembiochem. 2008 Dec 15;9(18):2913-9
18972466
Biochim Biophys Acta. 1998 Aug 14;1404(1-2):173-93
9714795
Eukaryot Cell. 2010 Jan;9(1):116-26
19897736
Curr Opin Cell Biol. 2004 Aug;16(4):436-42
15261677
Nature. 1990 Sep 20;347(6290):256-61
2144893
Trends Cell Biol. 1994 May;4(5):179-85
14731646
Science. 2008 Apr 18;320(5874):362-5
18420932
J Cell Biol. 1995 Oct;131(2):297-310
7593160
Curr Genet. 1994 Oct;26(4):285-94
7882421
Cell. 1993 Sep 10;74(5):855-61
8374953
Biochim Biophys Acta. 2007 Aug;1773(8):1311-40
17604854
Dev Cell. 2002 Mar;2(3):283-94
11879634
Cell. 1980 Aug;21(1):205-15
6996832
Cell. 1990 Jun 15;61(6):1063-74
2112425
J Cell Sci. 1995 Apr;108 ( Pt 4):1605-15
7615679
Chem Biol. 2005 Jan;12(1):55-63
15664515
PLoS Genet. 2008 Aug 08;4(8):e1000151
18688276
Nature. 2002 Jul 25;418(6896):387-91
12140549
Genetics. 1986 May;113(1):35-43
3519363
Nat Genet. 1996 Dec;14(4):450-6
8944025
Nat Cell Biol. 2004 Jun;6(6):483-6
15170459